Literature DB >> 26786412

Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders.

Sergi Ferré1.   

Abstract

BACKGROUND: The psychostimulant properties of caffeine are reviewed and compared with those of prototypical psychostimulants able to cause substance use disorders (SUD). Caffeine produces psychomotor-activating, reinforcing, and arousing effects, which depend on its ability to disinhibit the brake that endogenous adenosine imposes on the ascending dopamine and arousal systems.
OBJECTIVES: A model that considers the striatal adenosine A2A-dopamine D2 receptor heteromer as a key modulator of dopamine-dependent striatal functions (reward-oriented behavior and learning of stimulus-reward and reward-response associations) is introduced, which should explain most of the psychomotor and reinforcing effects of caffeine. HIGHLIGHTS: The model can explain the caffeine-induced rotational behavior in rats with unilateral striatal dopamine denervation and the ability of caffeine to reverse the adipsic-aphagic syndrome in dopamine-deficient rodents. The model can also explain the weaker reinforcing effects and low abuse liability of caffeine, compared with prototypical psychostimulants. Finally, the model can explain the actual major societal dangers of caffeine: the ability of caffeine to potentiate the addictive and toxic effects of drugs of abuse, with the particularly alarming associations of caffeine (as adulterant) with cocaine, amphetamine derivatives, synthetic cathinones, and energy drinks with alcohol, and the higher sensitivity of children and adolescents to the psychostimulant effects of caffeine and its potential to increase vulnerability to SUD.
CONCLUSIONS: The striatal A2A-D2 receptor heteromer constitutes an unequivocal main pharmacological target of caffeine and provides the main mechanisms by which caffeine potentiates the acute and long-term effects of prototypical psychostimulants.

Entities:  

Keywords:  Adenosine; Alcohol; Caffeine; Dopamine; Drug abuse; Psychostimulants; Receptor heteromer

Mesh:

Substances:

Year:  2016        PMID: 26786412      PMCID: PMC4846529          DOI: 10.1007/s00213-016-4212-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  208 in total

Review 1.  Putting a spin on the dorsal-ventral divide of the striatum.

Authors:  Pieter Voorn; Louk J M J Vanderschuren; Henk J Groenewegen; Trevor W Robbins; Cyriel M A Pennartz
Journal:  Trends Neurosci       Date:  2004-08       Impact factor: 13.837

2.  Effects of caffeine on performance and mood: withdrawal reversal is the most plausible explanation.

Authors:  Jack E James; Peter J Rogers
Journal:  Psychopharmacology (Berl)       Date:  2005-07-02       Impact factor: 4.530

3.  Differential glutamate-dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments.

Authors:  Janusz Borycz; M Fátima Pereira; Alessia Melani; Ricardo J Rodrigues; Attila Köfalvi; Leigh Panlilio; Felicita Pedata; Steven R Goldberg; Rodrigo A Cunha; Sergi Ferré
Journal:  J Neurochem       Date:  2007-01-24       Impact factor: 5.372

4.  Methylxanthines reverse the adipsic and aphagic syndrome induced by bilateral 6-hydroxydopamine lesions of the nigrostriatal pathway in rats.

Authors:  M Casas; G Prat; P Robledo; M Barbanoj; J Kulisevsky; F Jané
Journal:  Pharmacol Biochem Behav       Date:  2000-06       Impact factor: 3.533

5.  Changes in the ambulatory activity and discriminative stimulus effects of psychostimulant drugs in rats chronically exposed to caffeine: effect of caffeine dose.

Authors:  M Gasior; M Jaszyna; J Peters; S R Goldberg
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

6.  Evidence for addiction-like behavior in the rat.

Authors:  Véronique Deroche-Gamonet; David Belin; Pier Vincenzo Piazza
Journal:  Science       Date:  2004-08-13       Impact factor: 47.728

7.  Visual hemineglect induced by unilateral striatal dopamine deficiency in monkeys.

Authors:  N Miyashita; O Hikosaka; M Kato
Journal:  Neuroreport       Date:  1995-06-19       Impact factor: 1.837

8.  Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice.

Authors:  S Ferré; M Herrera-Marschitz; M Grabowska-Andén; M Casas; U Ungerstedt; N E Andén
Journal:  Eur J Pharmacol       Date:  1991-01-03       Impact factor: 4.432

Review 9.  Reward and aversion in a heterogeneous midbrain dopamine system.

Authors:  Stephan Lammel; Byung Kook Lim; Robert C Malenka
Journal:  Neuropharmacology       Date:  2013-04-08       Impact factor: 5.250

10.  Conditioned flavour preference negatively reinforced by caffeine in human volunteers.

Authors:  M R Yeomans; H Spetch; P J Rogers
Journal:  Psychopharmacology (Berl)       Date:  1998-06       Impact factor: 4.530

View more
  35 in total

1.  Caffeine Induces a Stimulant Effect and Increases Dopamine Release in the Nucleus Accumbens Shell Through the Pulmonary Inhalation Route of Administration in Rats.

Authors:  Martín Galvalisi; José Pedro Prieto; Marcela Martínez; Juan Andrés Abin-Carriquiry; Cecilia Scorza
Journal:  Neurotox Res       Date:  2016-09-08       Impact factor: 3.911

2.  Caffeine, a common active adulterant of cocaine, enhances the reinforcing effect of cocaine and its motivational value.

Authors:  José Pedro Prieto; Cecilia Scorza; Gian Pietro Serra; Valentina Perra; Martín Galvalisi; Juan Andrés Abin-Carriquiry; Giovanna Piras; Valentina Valentini
Journal:  Psychopharmacology (Berl)       Date:  2016-06-07       Impact factor: 4.530

3.  Effects of caffeine on alcohol reinforcement: beverage choice, self-administration, and subjective ratings.

Authors:  Mary M Sweeney; Steven E Meredith; Daniel P Evatt; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2017-01-20       Impact factor: 4.530

4.  Behavioral economic analysis of the reinforcing effects of "bath salts" mixtures: studies with MDPV, methylone, and caffeine in male Sprague-Dawley rats.

Authors:  Brenda M Gannon; Melson P Mesmin; Agnieszka Sulima; Kenner C Rice; Gregory T Collins
Journal:  Psychopharmacology (Berl)       Date:  2018-09-29       Impact factor: 4.530

5.  Adenosine A1-Dopamine D1 Receptor Heteromers Control the Excitability of the Spinal Motoneuron.

Authors:  Marla Rivera-Oliver; Estefanía Moreno; Yocasta Álvarez-Bagnarol; Christian Ayala-Santiago; Nicole Cruz-Reyes; Gian Carlo Molina-Castro; Stefan Clemens; Enric I Canela; Sergi Ferré; Vicent Casadó; Manuel Díaz-Ríos
Journal:  Mol Neurobiol       Date:  2018-05-24       Impact factor: 5.590

Review 6.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

7.  Serum miRNAs are differentially altered by ethanol and caffeine consumption in rats.

Authors:  M Martinez; I M U Rossetto; R M S Arantes; F S N Lizarte; L F Tirapelli; D P C Tirapelli; L G A Chuffa; F E Martinez
Journal:  Toxicol Res (Camb)       Date:  2019-07-17       Impact factor: 3.524

8.  Caffeine inhibits hypoxia-induced nuclear accumulation in HIF-1α and promotes neonatal neuronal survival.

Authors:  Hsiu-Ling Li; Nahla Zaghloul; Ijaz Ahmed; Anton Omelchenko; Bonnie L Firestein; Hai Huang; Latoya Collins
Journal:  Exp Neurol       Date:  2019-02-26       Impact factor: 5.330

9.  Role of monoaminergic systems and ambient temperature in bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV)-elicited hyperthermia and locomotor stimulation in mice.

Authors:  Brenda M Gannon; Adrian Williamson; Kenner C Rice; William E Fantegrossi
Journal:  Neuropharmacology       Date:  2017-09-05       Impact factor: 5.250

10.  Cognitive impairments by alcohol and sleep deprivation indicate trait characteristics and a potential role for adenosine A1 receptors.

Authors:  Eva-Maria Elmenhorst; David Elmenhorst; Sibylle Benderoth; Tina Kroll; Andreas Bauer; Daniel Aeschbach
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.